-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
New Biosynthetic Psilocybin Hits The Psychedelics Market, Available For Research And Clinical Trials
New Biosynthetic Psilocybin Hits The Psychedelics Market, Available For Research And Clinical Trials
With psilocybin among the favorites within psychedelics, Core One Labs Inc. (OTCQB:CLABF) is joining Optimi Health (OTC:OPTHF) to formally begin sales for its own biosynthetic API psilocybin product.
On August 26, the company began discussions with a development and manufacturing partner regarding the commercial scale and GMP-compliant production of Core One's Active Pharmaceutical Ingredient (API) psilocybin product.
To that end, Core One's representatives contacted several pharmaceutical and publicly traded psychedelic companies in need of the psychedelic for studies and trials, as well as medical clinics, professionals and organizations conducting psychedelic research or therapy with whom they shared the news of the proprietary psilocybin's availability. The company's business approach includes complementary lines of businesses and units. Besides its subsidiaries' work on psilocybin production system using engineered bacteria, psychedelic-based novel compounds and additional synthetic technologies for psilocybin and psilocin production methods, Core One holds an interest in four medical clinics with a combined database of more than 275,000 patients.
"Our cost-efficient API biosynthetic psilocybin is garnering strong interest from companies, and research groups who are looking for a supply of psilocybin," Core One's CEO Joel Shacker said. "I believe that Core One will become a market leader in the supply of psilocybin due to being one of the first companies to market with an API grade compound, as well as the other competitive advantages the company has."
Photo Courtesy of Olia Danilevich on Pexels.
With psilocybin among the favorites within psychedelics, Core One Labs Inc. (OTCQB:CLABF) is joining Optimi Health (OTC:OPTHF) to formally begin sales for its own biosynthetic API psilocybin product.
使用裸盖菇素其中迷幻药中最受欢迎的, Core One Labs Inc.(OTCQB:CLABF)正在加入乐美健康(OTC:OPTHF)正式开始销售自己的生物合成原料药裸盖菇素产品。
On August 26, the company began discussions with a development and manufacturing partner regarding the commercial scale and GMP-compliant production of Core One's Active Pharmaceutical Ingredient (API) psilocybin product.
8月26日,该公司开始与一家开发和制造合作伙伴关于商业规模和符合GMP的生产Core One的活性药物成分(API)裸盖菇素产品。
To that end, Core One's representatives contacted several pharmaceutical and publicly traded psychedelic companies in need of the psychedelic for studies and trials, as well as medical clinics, professionals and organizations conducting psychedelic research or therapy with whom they shared the news of the proprietary psilocybin's availability. The company's business approach includes complementary lines of businesses and units. Besides its subsidiaries' work on psilocybin production system using engineered bacteria, psychedelic-based novel compounds and additional synthetic technologies for psilocybin and psilocin production methods, Core One holds an interest in four medical clinics with a combined database of more than 275,000 patients.
为此,Core One的代表联系了几家需要迷幻药进行研究和试验的制药和上市迷幻药公司,以及进行迷幻研究或治疗的医疗诊所、专业人员和组织,他们与他们分享了迷幻药的消息专有裸盖菇素的可用性。该公司的业务方式包括业务和单位的互补性。除了子公司使用工程菌生产裸盖菇素系统、基于迷幻剂的新化合物以及裸盖菇素和裸盖菇素生产方法的额外合成技术外,Core One还持有四家医疗诊所拥有一个合并的数据库超过275,000名患者。
"Our cost-efficient API biosynthetic psilocybin is garnering strong interest from companies, and research groups who are looking for a supply of psilocybin," Core One's CEO Joel Shacker said. "I believe that Core One will become a market leader in the supply of psilocybin due to being one of the first companies to market with an API grade compound, as well as the other competitive advantages the company has."
Core One的首席执行官乔尔·沙克说:“我们经济高效的原料药生物合成裸盖菇素引起了公司和研究机构的强烈兴趣,他们正在寻找裸盖菇素的供应。”我相信Core One将成为裸盖菇素供应的市场领先者,因为它是首批推出原料药级别化合物的公司之一,以及该公司拥有的其他竞争优势。“
Photo Courtesy of Olia Danilevich on Pexels.
照片由Olia Danilevich在Pexels上提供。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧